The reiteration of a Neutral rating and maintenance of the price target suggests that Cantor Fitzgerald's view on Alnylam Pharmaceuticals has not changed. This is likely to have a neutral short term impact on the stock as it does not alter the investment thesis or provide new information that would significantly change the market's perception of the company's value.